**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 80348

**Manuscript Type:** REVIEW

**Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment?**

Olguin JE *et al*. Immunotherapy on colorectal cancer

Jonadab E Olguin, Monica G Mendoza-Rodriguez, C Angel Sanchez-Barrera, Luis I Terrazas

**Jonadab E Olguin, Luis I Terrazas,** Laboratorio Nacional en Salud, Diagnóstico Molecular y Efecto Ambiental en Enfermedades Crónico-degenerativas, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Estado de Mexico, Mexico

**Monica G Mendoza-Rodriguez, C Angel Sanchez-Barrera, Luis I Terrazas,** Unidad de Biomedicina, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Estado de Mexico, Mexico

**Author contributions:** Olguin JE and Mendoza-Rodriguez MG contributed equally to this work; Olguin JE, Mendoza-Rodriguez MG, and Terrazas LI contributed to conception and design; Olguin JE and Terrazas LI contributed to the search for information related to the immune response; Mendoza-Rodriguez MG and Sanchez-Barrera CA contributed to the search for information related to chemotherapy; Olguin JE and Mendoza-Rodriguez MG contributed to figure development; Olguin JE, Mendoza-Rodriguez MG, Sanchez-Barrera CA, and Terrazas LI contributed to paper writing; Olguin JE, Mendoza-Rodriguez MG, and Terrazas LI contributed to funding resources.

**Corresponding author: Luis I Terrazas, PhD, Chairman, Senior Scientist,** Unidad de Biomedicina, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Avenida de los Barrios # 1, Tlalnepantla 54090, Estado de México, Mexico. literrazas@unam.mx

**Received:** September 24, 2022

**Revised:** November 3, 2022

**Accepted:** January 10, 2023

**Published online:**

**Abstract**

Colorectal cancer (CRC) is among the most prevalent and deadly neoplasms worldwide. According to GLOBOCAN predictions, its incidence will increase from 1.15 million CRC cases in 2020 to 1.92 million cases in 2040. Therefore, a better understanding of the mechanisms involved in CRC development is necessary to improve strategies focused on reducing the incidence, prevalence, and mortality of this oncological pathology. Surgery, chemotherapy, and radiotherapy are the main strategies for treating CRC. The conventional chemotherapeutic agent utilized throughout the last four decades is 5-fluorouracil, notwithstanding its low efficiency as a single therapy. In contrast, combining 5-fluorouracil therapy with leucovorin and oxaliplatin or irinotecan increases its efficiency. However, these treatments have limited and temporary solutions and aggressive side effects. Additionally, most patients treated with these regimens develop drug resistance, which leads to disease progression. The immune response is considered a hallmark of cancer; thus, the use of new strategies and methodologies involving immune molecules, cells, and transcription factors has been suggested for CRC patients diagnosed in stages III and IV. Despite the critical advances in immunotherapy, the development and impact of immune checkpoint inhibitors on CRC is still under investigation because less than 25% of CRC patients display an increased 5-year survival. The causes of CRC are diverse and include modifiable environmental factors (smoking, diet, obesity, and alcoholism), individual genetic mutations, and inflammation-associated bowel diseases. Due to these diverse causes, the solutions likely cannot be generalized. Interestingly, new strategies, such as single-cell multiomics, proteomics, genomics, flow cytometry, and massive sequencing for tumor microenvironment analysis, are beginning to clarify the way forward. Thus, the individual mechanisms involved in developing the CRC microenvironment, their causes, and their consequences need to be understood from a genetic and immunological perspective. This review highlighted the importance of altering the immune response in CRC. It focused on drugs that may modulate the immune response and show specific efficacy and contrasted with evidence that immunosuppression or the promotion of the immune response is the answer to generating effective treatments with combined chemotherapeutic drugs.

**Key Words:** Colorectal cancer; Immunotherapy checkpoint inhibitors; Chemotherapy; Immunotherapy; Immune response

Olguin JE, Mendoza-Rodriguez MG, Sanchez-Barrera CA, Terrazas LI. Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment? . *World J Gastrointest Oncol* 2022; In press

**Core Tip:** This review focused on the drugs that may modulate the immune response and show specific efficacy in the treatment of colorectal cancer. We then presented the evidence that immunosuppression or promotion of the immune response is the answer to generating effective treatments with combined chemotherapeutic drugs.

**INTRODUCTION**

The origin of colorectal cancer (CRC) is heterogeneous. The general classification of CRC is divided into inherited, sporadic, and intestinal bowel diseases. Inherited CRC, which represents approximately 5% of all CRC cases, includes either the presence or absence of colonic polyps, such as Lynch syndrome and serrated polyposis syndrome[1]. Sporadic CRC (approximately 70% of CRC cases) is sustained by environmental and modifiable risk factors, including stress, diet, and age. Sporadic CRC has a monoclonal origin and is characterized by mutation accumulation in oncogenes and tumor suppressor genes. The second pathway of CRC includes the traditionalAPC-KRAS pathway and the microsatellite instability group, both having an essential role in clinical studies[2]. The third pathway includes intestinal chronic inflammatory diseases, such as Crohn’s disease and ulcerative colitis, which could result in colitis-associated colon cancer[3].

From a biological perspective, this evidence demonstrates that the origin of CRC is diverse. The response to therapies is not always homogeneous in patients. The best treatment should be based on the tumor’s unique characteristics. Effective treatments need to be broad and involve chemical and immunological molecules. The context of the broad causes of CRC development is highly involved in the low effectiveness of either single chemotherapeutics or classical immunotherapy by checkpoints inhibitor (ICI) administration during this oncological pathology. An in-depth and more precise description of the CRC origin and development, including a role for both immune response and inflammation, can be found in[4,5].

**CONVENTIONAL TREATMENTS FOR COLON CANCER AND MECHANISMS OF ACTION FROM A GENETIC PERSPECTIVE**

CRC is one of the deadliest diseases in the world. Despite advances in diagnosis, treatment strategies remain an essential bottleneck affecting survival, in which the pathological stage represents the most important prognostic factor for patients with CRC. The accurate classification of lesions is the primary tool to decide the most appropriate treatment and therapy[6]. The treatment for early-stage CRC (stage I and stage II) currently consists of resecting the tumor area with regional lymph nodes, which has a 5-year disease-free survival rate of 95%[7]. In the advanced stage of the disease (stages III and above), the rate of disease-free survival drops from 90% to 50% for surgery alone, requiring the administration of chemotherapeutics, and only 17%-20% of these patients ultimately survive[8,9].

5-Fluorouracil (5-FU) has been central in treating advanced CRC since 1957. Unfortunately, the response rate to 5-FU as the first-line chemotherapy in advanced CRC is still only 10%-15%. In contrast, 5-FU combined with other anticancer drugs as adjuvants, such as leucovorin and oxaliplatin (FOLFOX) or leucovorin calcium and irinotecan, increases the effectiveness of 5-FU by 50%[10,11].

5-FU is the third most commonly used chemotherapeutic agent for the treatment of solid malignancies worldwide[12]. Heidelberger synthesized it in the early 1950s as a derivate of fluoropyrimidines. This drug was one of the first chemotherapeutics reported to have anticancer activity. It was tested in diverse tumors in rats and mice, where it significantly reduced tumor burden. Additionally, tumoral tissues incorporated this compound more rapidly than normal tissues, which pointed to its potential use as a chemotherapeutic drug[13,14]. In 1962, the Food and Drug Administration approved the use of 5-FU for treating CRC.

In intravenous administration, 5-FU is incorporated rapidly into the cells through facilitated transport as uracil[15]. Subsequently, its metabolism can be driven in two ways, *i.e.*, *via* anabolic and catabolic routes, which compete with each other. In sensitive cancerous cells, the anabolic pathway leads to the conversion of this drug into several active metabolites, such as fluorodeoxyuridine monophosphate, fluorodeoxyuridine triphosphate, and fluorouridine triphosphate[16]. The active metabolites interfere with nucleoside metabolism and can be incorporated into RNA and DNA, leading to cytotoxicity and cell death[17,18]. This mechanism is due to its similar structure to pyrimidine, molecules of DNA and RNA, an analog of uracil with a fluorine atom at the C-5 position in place of hydrogen[19]. Fluorodeoxyuridine monophosphate disrupts the function of thymidylate synthase, a key enzyme responsible for providing deoxynucleotide triphosphates, which are necessary for DNA replication and repair, catalyzing the reaction of deoxyuridine monophosphate to deoxythymidine monophosphate synthesis[14,15]. An insufficiency in deoxythymidine monophosphate leads to the depletion of deoxythymidine triphosphate, which perturbs the levels of the other deoxynucleotide triphosphates[16-20] (Figure 1).

5-FU has primarily been used in the treatment of solid cancers of digestive origin, such as colorectal, anal, pancreatic, esophageal, gastric, and ampullary tumors, and less frequently in breast, cervical, and head and neck cancers[21-23]. CRC treatment includes various chemotherapeutic drugs. As the backbone of treatments, 5-FU has been used for more than five decades, and more recently, it has been combined with other chemotherapeutic drugs to potentiate its anticarcinogenic effect[22,24].

The use of alternative broad-spectrum chemotherapeutics in addition to 5-FU has been proposed for colon cancer treatment. Doxorubicin treatment combined with other drugs, such as metformin and sodium oxamate, reduces the proliferation rate of colon cancer cell lines *in vitro*[25]. However, the use of doxorubicin in patients is limited by the side effects frequently associated with this drug, such as hepatotoxicity, nephrotoxicity, pulmotoxicity, and cardiotoxicity[26,27]. Additionally, doxorubicin can lead to chemoresistance in tumor cells through nuclear factor kappa B translocation to the nucleus and DNA binding because of the damage induced by this drug, triggering the expression of antiapoptotic genes[28].

In CRC, nuclear factor kappa B nuclear translocation is a characteristic in more than 70% of patients, limiting the use of doxorubicin[29]. Another disadvantage of this drug is its anthracycline nature since it is extracted from *Streptomyces spp*. Cancer cells frequently show rapid resistance to naturally occurring cancer drugs, diminishing their effectiveness, whereas they are more sensitive to antimetabolites, such as 5-FU and cisplatin, among others[30]. The use of other chemotherapeutics, such as tamoxifen, which is highly effective and frequently used in breast cancer treatment, has an adverse effect in the treatment of CRC[31]. Due to the molecular characteristics of each type of cancer, the successful use of tamoxifen in breast cancer lies in its mechanism of action. Approximately 80% of all breast cancers are positive for the estrogen receptor, and tamoxifen inhibits the expression of estrogen-regulated genes by the competitive inhibition of this receptor. Different reports indicate that tamoxifen has the opposite effect on CRC, increasing the risk of developing this type of cancer[31,32].

**MOLECULAR PERSPECTIVE FOR THE USE OF CHEMOTHERAPEUTIC STRATEGIES IN CRC TREATMENT: WHICH IS THE RIGHT DRUG?**

CRC is a molecularly heterogeneous disease in which genetics and cellular events accumulate to endow tumor cells with aggressive characteristics, including chemotherapy resistance. Chromosomal instability, mismatch repair, and methylator phenotype are the three major pathways involved in acquiring tumorigenesis and a malignant phenotype and could be present in sporadic and inherited CRC[33,34]. The choice of better therapy is based on cancer-related features and patient-related factors, such as the number and localization of metastases, tumor progression, presence or absence of biochemical markers, and comorbidity[35-37]. Despite all these characteristics, treatment based on the antineoplastic effects of 5-FU is the cornerstone of therapy in advanced CRC stages.

Treatment with 5-FU in combination with other drugs, such as oxaliplatin (OXA), irinotecan, capecitabine, bevacizumab, cetuximab, panitumumab, ziv-aflibercept, regorafenib, and ramucirumab, increases its effectiveness and has been approved by the Food and Drug Administration for the management of CRC[38]. Thus, during stages III or IV in resected CRC patients, the use of combination treatment, such as FOLFOX or 5-FU, leucovorin calcium, and irinotecan, is common as a first-line treatment. This strategy significantly increases the survival rate of these patients[39]. The initial chemotherapy scheme and the decision on better combinatory drugs depends on multiple conditions in the patients. In metastatic CRC limited to the liver or lung, surgery and the rapid initiation of chemotherapy appears to be the best option. When CRC cure is not possible, three additional scenarios can arise: (1) Patients with advanced tumors and symptoms require rapid tumor shrinkage to provide palliation, which begins with chemotherapy; (2) Asymptomatic patients with bulky tumor and possible rapid progression are likely to become symptomatic in a short period; and (3) Patients without symptoms but disseminated disease who never had resectable disease but whose tumors remain non-bulky are likely to remain asymptomatic for an extended period. In the last two scenarios, the initiation of chemotherapy can be discussed[22,40]. Previous work in the Nordic population demonstrated that early treatment with 5-FU plus leucovorin in asymptomatic patients with advanced CRC prolonged survival and delayed both disease progression and the onset of symptoms[41]. In another study in Australasian and Canadian populations of asymptomatic patients using the same chemotherapy regimen, no difference was reported between early or delayed chemotherapy use until symptoms appeared[42]. Thus, clinical treatment requires a medical discussion and the patient´s preference when cure is not possible. The spectrum of molecular alterations that offer alternative management for this disease could be explored.

Alterations in genes related to survival, angiogenesis, proliferation, and apoptosis incorporate additional strategies into CRC treatment. The *RAS*, *KRAS*, and *NRAS* genes play an essential role as prognostic and predictive indicators in CRC treatment[43–45]. Mutations in the DNA at position 12 in the KRAS protein are significantly associated with a poor prognosis: a 5-year survival rate of approximately 3%[46]. Patients with this mutation are not candidates to receive treatment with monoclonal antibodies, such as cetuximab or panitumumab, which target the epidermal growth factor receptor (EGFR)[47-50]. Blocking EGFR represents the second line of treatment in patients with wild-type RAS together with the backbone 5-FU, leucovorin calcium, and irinotecan therapy. Therefore, the patient’s genetic and tumor-specific factors need to be considered when choosing chemotherapeutic and combination schemes to avoid resistance and undesired responses to these therapies.

Drug resistance and consequent therapy failure are the main problems clinicians face in treating different neoplasms, which limit the quality of life and long-term remission rates as a consequence of tumor growth and spreading leading to 90% of patients dying[51,52]. Drug resistance is a highly complex process that is commonly classified into two types: intrinsic and acquired. Both types of drug resistance lead to the regulation of molecular mechanisms of chemoresistance, such as the activation of transporter pumps, oncogenes, tumor suppressor genes, mitochondrial alteration, DNA repair, autophagy, epithelial-mesenchymal transition, cancer stemness, and exosomes[53,54].

In the intrinsic phenotype, diverse alterations existing before drug administration in the patient complicate the selection of chemotherapy. The inherent genetic mutations in tumors, such as a *KRAS* mutation in exon 2 in codon 12 or 13, are the most frequent mutations associated with poor prognosis and drug resistance in CRC[55,56]. Therapies based on the first line of treatment using FOLFOX or 5-FU, leucovorin calcium, and irinotecan plus cetuximab or panitumumab (anti-EGFR) are ineffective in patients with *KRAS* mutations[57]. Recent studies indicate that mutations in genes related to the pathways that regulate tumor cell survival and proliferation and inhibit apoptosis in tumor cells, such as *AKT1* and *CTNNB1*, contribute to 5-FU chemotherapeutic resistance in CRC. The *CTNNB1* gene encodes the β-catenin protein, which plays a crucial role in cancer by activating the Wnt/β-catenin signaling pathway. This pathway is associated with tumorigenesis and CRC resistance, and it upregulates genes and proteins, such as multidrug resistance gene (*MDR1*) and inhibitor of apoptosis (*Bcl2*), to induce epithelial-mesenchymal transition and regulate the tumor microenvironment (TME)[58-60].

**IS CHEMOTHERAPY AN INDUCER OF IMMUNOSUPPRESSION IN CRC?**

The heterogeneity of tumors, including CRC, consists of heterogeneity in cancer and infiltrated resident host cells, extracellular matrix, and immune and inflammatory cells, such as macrophages, dendritic cells, myeloid-derived suppressor cells, T cells, mast cells, and natural killer cells. These components comprise the TME, which has a dynamic composition[61]. It is well known that one of the main functions of the TME is to provide a protective function for tumor cells, inducing crosstalk between immune and nonimmune cells that leads to tumor-mediated immunosuppression, supporting tumor growth and survival[62]. Recent reports indicate that the TME in CRC contributes to cancer progression and drug resistance through high interstitial pressure, fibrosis, and the degradation of the therapeutic agent by enzymatic activity and inducing immunosuppression[61,63,64]. These findings indicate that the regulation of immune cells surrounding the tumor has a critical role in the response to therapies for CRC. Thus, chemotherapy and immunotherapies targeting the recovery activity of immune cells are likely necessary to fight CRC.

The study of the effect of chemotherapeutic drugs on immune cells is controversial. The central concept here is that chemotherapy reduces the capacity of the immune system to function, but how could a drug affect the capacity and efficiency of the immune response to induce an efficient post-treatment response? Perhaps the “original” concept has a flawed approach. Evidence suggests that after 5-FU treatment in a mouse model, bone marrow cellularity decreases, but platelets and thrombopoietin, which are close to the immune response, rebound[64,65]. Similarly, the serum of patients diagnosed with stage III/IV CRC who had received FOLFOX chemotherapy showed increased levels of heat shock protein 70, which belongs to the damage-associated molecular patterns recognized by innate receptors[66]. Later, *in* *vitro* studies showed that the supernatants of dying CRC cells treated with OXA and 5-FU induced a mature phenotype in dendritic cells coexpressing HLA-DR, CD80, and CD86 and producing interleukin-1β, tumor necrosis factor-α, and MIP-1α in a TLR-4-dependent manner[66]. These results strongly suggested that OXA/5-FU treatment induced the activation of the innate immune response during CRC. Additionally, increased numbers of myeloid-derived suppressor cells have been reported in a mouse model of thymoma, and treatment with 5-FU combined with gemcitabine selectively induced apoptosis in myeloid-derived suppressor cells. Consequently, increased antigen-specific CD8+ T cells produced more interferon-γ, generating a T cell antitumor response (Figure 2)[66].

Conversely, high levels of the chemokine CCL20 recruit regulatory T (Treg) cells in CRC patients resistant to FOLFOX[67]. However, in blood samples from metastatic FOLFOX-sensitive CRC patients, a reduced percentage of Foxp3+ Treg cells was recorded after treatment[68]. Therefore, the increase in Treg cells is associated with 5-FU chemoresistance. Thus, evidence of 5-FU chemotherapy suggests a role in the specific and direct reduction of suppressive immune cells during CRC. Additionally, the increased apoptosis-induced death of tumor cells by 5-FU could increase the ability of immune cells to recognize damage-associated molecular patterns released by these dying tumor cells, inducing protective inflammation. Evidence needs to be accumulated in this field to clarify whether chemotherapy may be an inducer of immune cell activation (Figure 3).

**CLASSICAL ICIS USED AS MONOTHERAPY DURING CRC**

The effectiveness of ICI as an immunotherapy treatment has been evaluated in the last decade. The efficacy of these agents is evident in liquid tumors, such as melanoma, leukemia, and solid non-small cell lung carcinoma. Classical ICIs used to treat these oncological pathologies are anti-programmed cell death 1 (PD1), anti-programmed cell death ligand 1 (PDL1), and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) monoclonal antibodies, where anti-CTLA4 has a lower clinical efficacy[68,69] (Table 1).

Diverse reports suggest single or combined therapy using different antibodies targeted against the same or another molecule. In melanoma therapy, nivolumab, a human immunoglobulin G4 anti-PD1 pathway monoclonal antibody, results in an overall survival (OS) rate of 72.9%, whereas the antineoplastic chemotherapeutic dacarbazine resulted in a survival rate of 42.1%[69]. In metastatic melanoma refractory to chemotherapy, treatment with ipilimumab, an anti-CTLA4 antibody, shows high efficacy when combined with anti-PD1 antibodies (either pembrolizumab or nivolumab)[70]. Additionally, nivolumab and ipilimumab combination treatment prolongs progression-free survival, mainly in patients with tumors testing positive for PDL1 expression[71]. Although *in vitro* studies suggested that atezolizumab, avelumab, and durvalumab, all anti-PDL1 antibodies, more effectively block PD1/PDL1 signaling (Figure 2)[72], evidence of the use of an anti-PDL1 antibody as a single approved treatment without immunotherapy or chemotherapy combination is insufficient to conclude their role in inducing protection in metastatic melanoma[73]. Immunotherapy with the anti-PDL1 antibody atezolizumab has been approved to treat non-small cell lung carcinoma combined with chemotherapy, and anti-PDL1 has been approved to treat triple-negative breast cancer[74,75]. Therefore, increased PDL1 expression in the TME of melanoma patients is an efficient marker to predict response to anti-PD1 treatments, which must be applied in all types of cancer when this immunotherapy is suggested[76].

Notwithstanding the successful use of immunotherapy in the neoplasms mentioned above, few reports show an influential role for classical monoclonal ICI using anti-CTLA4 and anti-PD1/PDL1 axis antibodies in CRC. Most clinical assays were disappointing. For example, tremelimumab, a human immunoglobulin G2 anti-CTLA4 antibody, did not produce clinically meaningful results when it was used as a monotherapy in patients with refractory metastatic CRC[77] (Table 1).

Another monotherapy treatment using nivolumab in CRC patients with microsatellite instability and FOLFOX chemoresistance showed excellent control of the disease, and patients tolerated this treatment well[78]. CRC patients treated with nivolumab combined with an oral heat shock protein 90 inhibitor showed safety profiles and antitumor activity associated with reduced activity of Treg cells and better response of tumor-infiltrating lymphocytes[79]. Interestingly, a report of a woman treated with nivolumab for melanoma with no hereditary CRC background developed colon carcinoma after 7 years of anti-melanoma treatment. The medical service then decided to switch the treatment to ipilimumab, and after four cycles of monotherapy, the colon tumor was in complete remission[80]. Pembrolizumab used as monotherapy in either microsatellite instability-high or mismatch repair-deficient CRC patients produced improvements in health-related quality of life compared to patients treated with leucovorin, 5-FU, and OXA[81]. In one study of refractory mismatch repair, CRC patients treated with pembrolizumab as monotherapy plus maraviroc, an agonist of CCR5 that promotes the activation and recruitment of macrophages inducing immune cell infiltrate in tumors, showed a beneficial toxicity pattern. The OS was higher than expected[82].

ICI with avelumab monotherapy in unresectable metastatic CRC patients who failed FOLFOX chemotherapy showed an OS of 72.2% at 8.1 mo, which was similar to the effect of ICI monotherapy using either pembrolizumab or nivolumab. However, some patients showed treatment-related adverse events[83]. Durvalumab used as monotherapy in microsatellite-instability high/mismatch repair-deficient metastatic CRC patients whose disease had progressed after chemotherapy showed efficiency and a satisfactory progression-free survival of 58.2%; however, side effects were found in 36.4% of patients[84].

Taken together, these results suggest that contrary to anti-CTLA4, ICI monotherapy blocking the PD1/PDL1 axis has a better effect in high microsatellite instability/mismatch repair-deficient metastatic CRC patients who previously displayed chemoresistance. Additionally, combining ICI PD1/PDL1 monotherapy with either antibodies or immune cell stimulators improves treatment efficacy. However, only a small number of clinical trials show increased OS (Table 1). Most likely, the TME reduces the access of ICI antibodies to the target molecules expressed in either immune or epithelial cells (Figure 3).

**DOES COMBINED IMMUNOTHERAPY INCREASE THE EFFECTIVENESS OF TREATMENT FOR CRC?**

Little evidence of the apparent effect of ICI monotherapy on CRC development is available. Conversely, increasing evidence suggests a better outcome using combined ICI, *i.e.*, the use of two monoclonal antibodies targeting CTLA4 or the PD1/PDL1 axis. To improve the immune response, combination treatment with tremelimumab and durmalumab was used in patients for the preoperative management of resectable CRC and liver metastases. These patients improved their OS to 24.5 mo; interestingly, their CD4+, CD8+, and B cells displayed an activated profile[85]. Additionally, first-line treatment consisting of nivolumab plus low-dose ipilimumab treatment in patients with microsatellite instability and metastatic CRC without previous chemotherapy showed that this combination was well tolerated at the primary endpoint, with robust and durable clinical benefit. However, the study is ongoing, and OS data are not yet available[86]. Previous ICI studies using similar inclusion criteria and antibody doses showed that follow-up over 12 mo of combined treatment resulted in an 85% OS[87]. Recently, the combined use of ipilimumab plus nivolumab before surgery in either mismatch repair-deficient or mismatch repair-proficient CRC patients induced an antitumoral response associated with a lack of signs of cancer after surgery with increased infiltration of CD8+PD1+ cells; the authors suggested that this combined ICI therapy may be the standard treatment for mismatch repair-deficient CRC patients[21].

Additionally, circulating tumor DNA detection in the blood of patients with durable and ongoing responses to ipilimumab plus nivolumab could be used as a monitoring response and dynamic marker of this combined ICI treatment[88,89]. Finally, a study attempted to analyze whether pseudo progression was observed in mismatch repair-deficient CRC patients treated with nivolumab plus ipilimumab, showing that this treatment rarely induces and confirming a high disease control rate of 86%[90]. Taken together, this evidence strongly suggests that the combined ICI blockade of CTLA4-PD1/PDL1 in mismatch repair-deficient CRC patients is highly successful. However, these patients represent only a tiny fraction of all CRC-diagnosed patients. Therefore, more clinical trials must be developed to obtain sufficient evidence to conclude the positive effects of the classic ICI combination.

**USE OF EITHER MONOTHERAPY OR COMBINED IMMUNOTHERAPY PLUS CHEMOTHERAPY TO INCREASE THE EFFECTIVENESS OF TREATMENTS FOR CRC**

The combined use of atezolizumab plus aobimetinib, a MAPK/ERK kinase 1 and 2 inhibitor that increases CD8+ cell infiltration in tumors of patients with microsatellite-stable metastatic CRC, showed no improvement in OS and was consistent with the safety of using both drugs[91] (Table 1). A similar effect showing only acceptable tolerance to this treatment was observed with durmalumab plus inhibitor of MAPK/ERK kinase in microsatellite-stable metastatic CRC patients[89]. No improved OS was observed using atezolizumab combined with cobimetinib in metastatic CRC patients[92]. A multicenter phase I/II study in June 2017 aimed to analyze the role of durmalumab plus tremelimumab combined with FOLFOX chemotherapy in patients with metastatic CRC, expecting a 6-mo progression-free survival of over 70.7%; however, the authors do not have the final results to date[93].

Recently, the combination of atezolizumab with FOLFOX chemotherapy plus bevacizumab (monoclonal anti-vascular endothelial growth factor antibody) in mismatch repair metastatic CRC patients induced a median progression-free survival of 13 mo, while FOLFOX plus bevacizumab alone resulted in 11 mo of progression-free survival, suggesting that the addition of atezolizumab improves progression-free survival. However, 42% of patients showed neutropenia, and 27% displayed severe adverse events[94]. The same treatment consisting of atezolizumab combined with FOLFOX plus bevacizumab was used in patients with untreated unresectable metastatic CRC, showing no improvement in OS and safety signals[95]. The use of the anti-EGFR antibody cetuximab plus avelumab for treating wild-type *RAS* metastatic CRC patients was safe; the authors suggested that an analysis of circulating DNA in plasma could be an indicator of the positive effects of this treatment. However, the data are insufficient to show the impact on the OS rate[96].

Treatment with cetuximab plus the ICI avelumab in microsatellite stable metastatic CRC patients showed that subclones of tumors expressing PDL1 mutations mediated the resistance to direct avelumab antitumor effects but also increased T cell killing[97]. An analysis of the neutrophil-to-lymphocyte ratio in the blood of chemorefractory metastatic CRC patients treated with cetuximab plus avelumab showed that a high neutrophil-to-lymphocyte ratio was a poor prognostic factor. Thus, the neutrophil-to-lymphocyte ratio could also be a predictor for the effectiveness of the combined ICI cetuximab plus avelumab[98].

Regorafenib, an inhibitor of protein kinases in tumor angiogenesis used in combination with avelumab in microsatellite stable CRC patients, showed increased infiltration of CD8+ T cells associated with better outcomes, with an OS of 10.8 mo[99]. Metastatic CRC patients who previously received two radiotherapies and who were treated with durvalumab plus tremelimumab before the third round of radiotherapy showed increased circulating, differentiated, and proliferating CD8+ T cells, but the authors concluded that this finding does not meet the prespecified endpoint criteria to consider this combined ICI plus radiotherapy worthwhile for further study; specifically, the authors suggested an objective response rate of at least 25%, but they only obtained a response rate of 8.3%[100].

The addition of FOLFOX-based chemotherapy to avelumab plus an adenovirus vector vaccine capable of inducing a CD4+/CD8+ T cell response in mismatch repair-deficient microsatellite instability-high metastatic CRC patients showed no improvement in progression-free survival[101]. However, The Canadian Cancer Trials Group suggests that combining tremelimumab and durmalumab to treat patients with high microsatellite instability who had previously received chemotherapy (fluoropyrimidines, OXA, irinotecan, and others) may prolong OS. They correlated the increased effectiveness of this immunotherapy combination with the tumor mutation burden elevated in plasma[102].

It is essential to mention that some research about the combination of chemotherapy and ICI is under development[93]. For example, a phase II trial in 2020 will show whether atezolizumab combined with OXA, radiotherapy, and bevacizumab may increase progression-free survival in microsatellite instability CRC patients[103]. Additionally, in microsatellite instability-high metastatic CRC patients with deficient mismatch repair, a study is currently underway to prove the improvement of disease-free survival by ICI with avelumab plus fluoropyrimidine; the authors suggested that this ICI plus chemotherapy treatment would improve the expected 3-year disease-free survival rate by 12%[104]. Evidence showing that combining ICI with chemotherapy improves treatment efficacy continues to accumulate.

Most clinical trials reported here are recent, and perhaps the evidence is insufficient to conclude that a treatment criterion has already been established. Consequently, evidence supports the hypothesis that the use of classical ICIs improves chemotherapy treatment, mainly in CRC patients with high microsatellite instability. It is crucial for patients who do not have a good prognosis with chemotherapy alone to have a better response with the combination of classical ICI antibodies.

**MULTIOMICS, INDIVIDUALIZED IMMUNOTHERAPY, ADOPTIVE TRANSFER OF “TRAINED” IMMUNE CELLS, AND NONCLASSICAL ICIS ARE A NEW HOPE FOR CRC**

In recent years, mechanisms have begun to be developed to understand and explain why, in some cases, classical immunotherapy is sufficient to generate benefits in some patients. Multiple factors participate in the development of any pathology, such as the patient’s clinical history, genetics, and the ability of their immune cells to act during cancer. We emphasize the importance of the recruitment of immune cells to the TME; in the case of melanoma, non-small cell lung cancer, and leukemia, the capacity of the immune cells to access is greater, which together with ICIs increases the bioavailability of monoclonal antibodies to find the antigens expressed in the required enclosures to be detected and removed or blocked[105]. In contrast, other types of oncological pathologies are available when access to the tumor site is more difficult for both immune cells and classical ICI antibodies, such as CRC[106]. In addition, the causes of CRC are multiple, and we cannot attempt to generalize a unique treatment for all varieties of CRC to reduce the statistics of this oncological pathology on the rise.

The single-cell multiomics technique has shed light on the complexity of the individual immune response elicited against any agent. This approach facilitates the individual characterization of groups of cells by identifying the gene transcripts at a specific time[107]. This technique depends on the efficiency of flow cytometry to distinguish and separate individual cells, the equipment used to amplify mRNA transcripts and synthesize complementary strand DNA, and sequencing equipment, allowing for robust data with high precision and certainty[108]. The advancement of these latest-generation technologies allows not only the expression of the classic ICI (CTLA4, PD1/PDL1) to be distinguished but also the characterization of mRNA transcripts in specific immune or epithelial cell populations at a particular time. These transcripts, already expressed as proteins, can individually be proposed as new nonclassical ICIs in patients[109], generating a wide range of therapeutic targets that, as in the case of CRC, increase the efficiency of previous treatments.

Some surface molecules involved in suppressive functions for activated T cells, Treg cells, macrophages, neutrophils, and epithelial cells have been proposed as immunotherapy targets. Glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), T cell immunoglobulin and mucin domain 3 (TIM3), LAG3, CD39, CD73, CD47, and SIRP-1α (a do not eat me signal)[110] warrant evaluation as monotherapy or combined therapy in CRC.

TIM3 is an overexpressed inhibitory receptor in active immune cells, including myeloid and lymphoid cells, with suppressive and modulatory characteristics. It is relevant in reducing interferon-γ production by helper T type 1 cells after binding to its ligand, galectin-9[111]. TIM3 is also overexpressed by Treg cells in a colitis-associated colon cancer mouse model[112]. The combination of TIM3 with anti-PD1 ICI antibodies is a good prospect in a murine breast cancer model[113]. Sabatolimab, an anti-TIM3 antibody, has already been used as a treatment in ovarian, CRC, and non-small cell lung cancer combined with an anti-PD1 antibody, being well tolerated and improving antitumor activity[114]. GITR has a role in the immunomodulation of effector T cells and increases tumor resistance[113,115]. Treatment with an anti-GITR antibody combined with pembrolizumab improves the disease control rate compared with anti-GITR used as monotherapy for treating CRC, melanoma, and adrenal carcinoma[116].

Lymphocyte activation gene-3 (LAG3 or CD223) has a structure similar to that of the CD4 molecule, joining major histocompatibility complex II in antigen-presenting cells. However, two of their immunoglobulin-like domains can bind receptors in tumor cells[81]. Blockage of LAG3 induces increased interleukin-2 production and enhances T cell proliferation[117]. Therefore, LAG3 has been proposed as an ICI; the genes *LAG3* and *IDO1* were shown to be overexpressed in a phase II study of pembrolizumab use as ICI monotherapy in patients with esophageal squamous cell carcinoma. The authors suggested that a combination of ICIs is needed to induce immunity against this tumor[118]. CD73 is an extracellular adenosine receptor expressed in immunosuppressant cells (such as Treg cells), favoring tumor progression[119].

Recently, single-cell RNA sequencing in a colitis-associated CRC murine model showed that an anti-CD73 antibody has a significant role in improving the anticancer functions of Treg cells, and exhausted CD8+ T cells became activated CD8+ T cells. In contrast, anti-PD1 antibodies in the same model depleted Treg cells and M2 macrophages[120], suggesting a synergistic role for the new ICI anti-CD73 that may improve the positive effects of anti-PD1 monotherapy. *Ex vivo* samples of blood and tumors from microsatellite instability CRC patients showed that atezolizumab alone could reactivate T cells.

Furthermore, adding tiragolumab, an anti-TIGIT antibody, restored intraepithelial CD4 T and CD8 T cell function by favoring interferon-γ and tumor necrosis factor-α production[120,121]. TIGIT is a receptor upregulated in natural killer and activated T cells when the modulation of their effector abilities is necessary for the microenvironment, such as cancer. It is also overexpressed in Treg cells[122]. The use of avelumab plus the adoptive transfer of autologous dendritic cell vaccine in chemotherapy-treated mismatch repair-proficient metastatic CRC patients had a successful result because this treatment was well tolerated. Furthermore, treatment was terminated early because 11% of patients were disease free at 6 mo, and progression-free survival was increased by 40%[123]. This evidence also suggests that new ICI research could open other possibilities for specific and beneficial treatment for CRC patients because either immune or epithelial cells may express nonclassical ICI molecules (Figure 2).

**CONCLUSION**

Chemotherapy using 5-FU remains the primary treatment for CRC, despite its high toxicity and low efficacy. New strategies targeting ICIs have been useful in some oncological pathologies; however, evidence showing the effectiveness of classical ICI monotherapy in CRC is scarce. A combination of classical ICI antibodies targeting CTLA4 and PD1/PDL1 molecules showed stronger efficacy for CRC treatment. Finally, classical ICI plus conventional chemotherapy is effective, as evidenced by increased OS, but these strategies are not yet well established, and some clinical studies are ongoing. Evidence suggests that chemotherapy produces neoantigens, increasing tumor immunogenicity that may activate immune responses[124]. This increased immunogenicity is likely the reason for a better response when classical ICI plus chemotherapy is used and may represent a pathway to design new therapeutic strategies aimed at improving the response in CRC patients based on immunological reactivation combined with conventional chemotherapy. Knowledge of the TME in CRC is essential to understand immunosuppression. New options for nonclassical ICIs obtained by single-cell sequencing are shedding light on this area and will probably improve the effectiveness of many treatments.

We are possibly on the verge of major findings in the study of CRC, where the immune response will continue playing a leading role and where new proposals with nonclassical ICIs may reduce the current statistics and poor prognoses for this oncological pathology.

**REFERENCES**

1 **Øines M**, Helsingen LM, Bretthauer M, Emilsson L. Epidemiology and risk factors of colorectal polyps. *Best Pract Res Clin Gastroenterol* 2017; **31**: 419-424 [PMID: 28842051 DOI: 10.1016/j.bpg.2017.06.004]

2 **Yamagishi H**, Kuroda H, Imai Y, Hiraishi H. Molecular pathogenesis of sporadic colorectal cancers. *Chin J Cancer* 2016; **35**: 4 [PMID: 26738600 DOI: 10.1186/s40880-015-0066-y]

3 **Shah SC**, Itzkowitz SH. Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. *Gastroenterology* 2022; **162**: 715-730.e3 [PMID: 34757143 DOI: 10.1053/j.gastro.2021.10.035]

4 **Medina-Andrade I**, Olguín JE, Rodriguez T, Terrazas LI. Chapter 7- The inflammation during colorectal cancer: A friend or a foe? In: Morales-Montor J, Segovia-Mendoza M. Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives. Academic Press, 2021: 103-129

5 **Morales-Montor J**. The Innate Immune System in Health and Disease: From the Lab Bench Work to Its Clinical Implications. Volume 1. Nova Science Publishers Incorporated, 2022

6 **Wolpin BM**, Mayer RJ. Systemic treatment of colorectal cancer. *Gastroenterology* 2008; **134**: 1296-1310 [PMID: 18471507 DOI: 10.1053/j.gastro.2008.02.098]

7 **Osterman E**, Glimelius B. Recurrence Risk After Up-to-Date Colon Cancer Staging, Surgery, and Pathology: Analysis of the Entire Swedish Population. *Dis Colon Rectum* 2018; **61**: 1016-1025 [PMID: 30086050 DOI: 10.1097/DCR.0000000000001158]

8 **Wilkinson NW**, Yothers G, Lopa S, Costantino JP, Petrelli NJ, Wolmark N. Long-term survival results of surgery alone *vs* surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. *Ann Surg Oncol* 2010; **17**: 959-966 [PMID: 20082144 DOI: 10.1245/s10434-009-0881-y]

9 **Böckelman C**, Engelmann BE, Kaprio T, Hansen TF, Glimelius B. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. *Acta Oncol* 2015; **54**: 5-16 [PMID: 25430983 DOI: 10.3109/0284186X.2014.975839]

10 **Gu J**, Li Z, Zhou J, Sun Z, Bai C. Response prediction to oxaliplatin plus 5-fluorouracil chemotherapy in patients with colorectal cancer using a four-protein immunohistochemical model. *Oncol Lett* 2019; **18**: 2091-2101 [PMID: 31423282 DOI: 10.3892/ol.2019.10474]

11 **Tournigand C**, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol* 2004; **22**: 229-237 [PMID: 14657227 DOI: 10.1200/JCO.2004.05.113]

12 **Grem JL**. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. *Invest New Drugs* 2000; **18**: 299-313 [PMID: 11081567 DOI: 10.1023/a:1006416410198]

13 **Heidelberger C**, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. *Nature* 1957; **179**: 663-666 [PMID: 13418758 DOI: 10.1038/179663a0]

14 **Rutman RJ**, Cantarow A, Paschkis KE. The catabolism of uracil *in vivo* and in vitro. *J Biol Chem* 1954; **210**: 321-329 [PMID: 13201593]

15 **Wohlhueter RM**, McIvor RS, Plagemann PG. Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. *J Cell Physiol* 1980; **104**: 309-319 [PMID: 7419607 DOI: 10.1002/jcp.1041040305]

16 **Longley DB**, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. *Nat Rev Cancer* 2003; **3**: 330-338 [PMID: 12724731 DOI: 10.1038/nrc1074]

17 **Thomas DM**, Zalcberg JR. 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. *Clin Exp Pharmacol Physiol* 1998; **25**: 887-895 [PMID: 9807659 DOI: 10.1111/j.1440-1681.1998.tb02339.x]

18 **Noordhuis P**, Holwerda U, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Pinedo HM, Peters GJ. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. *Ann Oncol* 2004; **15**: 1025-1032 [PMID: 15205195 DOI: 10.1093/annonc/mdh264]

19 **Rutman RJ**, Cantarow A, Paschkis KE. Studies in 2-acetylaminofluorene carcinogenesis. III. The utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma. *Cancer Res* 1954; **14**: 119-123 [PMID: 13126946]

20 **Miura K**, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, Shibata C, Sasaki I. 5-fu metabolism in cancer and orally-administrable 5-fu drugs. *Cancers (Basel)* 2010; **2**: 1717-1730 [PMID: 24281184 DOI: 10.3390/cancers2031717]

21 **Chalabi M**, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda M, Grootscholten C, Beets GL, Snaebjornsson P, Maas M, Mertz M, Veninga V, Bounova G, Broeks A, Beets-Tan RG, de Wijkerslooth TR, van Lent AU, Marsman HA, Nuijten E, Kok NF, Kuiper M, Verbeek WH, Kok M, Van Leerdam ME, Schumacher TN, Voest EE, Haanen JB. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. *Nat Med* 2020; **26**: 566-576 [PMID: 32251400 DOI: 10.1038/s41591-020-0805-8]

22 **Vodenkova S**, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. *Pharmacol Ther* 2020; **206**: 107447 [PMID: 31756363 DOI: 10.1016/j.pharmthera.2019.107447]

23 **Robertson J**, Barr R, Shulman LN, Forte GB, Magrini N. Essential medicines for cancer: WHO recommendations and national priorities. *Bull World Health Organ* 2016; **94**: 735-742 [PMID: 27843163 DOI: 10.2471/BLT.15.163998]

24 **Sargent D**, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, de Gramont A. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. *J Clin Oncol* 2009; **27**: 872-877 [PMID: 19124803 DOI: 10.1200/JCO.2008.19.5362]

25 **Coronel-Hernández J**, Salgado-García R, Cantú-De León D, Jacobo-Herrera N, Millan-Catalan O, Delgado-Waldo I, Campos-Parra AD, Rodríguez-Morales M, Delgado-Buenrostro NL, Pérez-Plasencia C. Combination of Metformin, Sodium Oxamate and Doxorubicin Induces Apoptosis and Autophagy in Colorectal Cancer Cells *via* Downregulation HIF-1α. *Front Oncol* 2021; **11**: 594200 [PMID: 34123772 DOI: 10.3389/fonc.2021.594200]

26 **Soulières D**, Greer W, Magliocco AM, Huntsman D, Young S, Tsao MS, Kamel-Reid S. KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. *Curr Oncol* 2010; **17 Suppl 1**: S31-S40 [PMID: 20680106 DOI: 10.3747/co.v17is1.614]

27 **Hasbal-Celikok G**, Aksoy-Sagirli P, Altiparmak-Ulbegi G, Can A. Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment. *Oncol Lett* 2021; **21**: 209 [PMID: 33574948 DOI: 10.3892/ol.2021.12470]

28 **Tong J**, Ganguly PK, Singal PK. Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. *Am J Physiol* 1991; **260**: H909-H916 [PMID: 2000986 DOI: 10.1152/ajpheart.1991.260.3.H909]

29 **Injac R**, Radic N, Govedarica B, Perse M, Cerar A, Djordjevic A, Strukelj B. Acute doxorubicin pulmotoxicity in rats with malignant neoplasm is effectively treated with fullerenol C60(OH)24 through inhibition of oxidative stress. *Pharmacol Rep* 2009; **61**: 335-342 [PMID: 19443948 DOI: 10.1016/s1734-1140(09)70041-6]

30 **Bednarski BK**, Baldwin AS Jr, Kim HJ. Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin. *PLoS One* 2009; **4**: e6992 [PMID: 19746155 DOI: 10.1371/journal.pone.0006992]

31 **Lind DS**, Hochwald SN, Malaty J, Rekkas S, Hebig P, Mishra G, Moldawer LL, Copeland EM 3rd, Mackay S. Nuclear factor-kappa B is upregulated in colorectal cancer. *Surgery* 2001; **130**: 363-369 [PMID: 11490372 DOI: 10.1067/msy.2001.116672]

32 **Nooter K**, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. *Pathol Res Pract* 1996; **192**: 768-780 [PMID: 8880878 DOI: 10.1016/S0344-0338(96)80099-9]

33 **Chen S**, Liu H, Li J, Yang G. Risk of Gastric and Colorectal Cancer After Tamoxifen Use for Breast Cancer: A Systematic Review and Meta-Analysis. *J Clin Gastroenterol* 2015; **49**: 666-674 [PMID: 25319737 DOI: 10.1097/MCG.0000000000000262]

34 **Goodsell DS**. The molecular perspective: tamoxifen and the estrogen receptor. *Oncologist* 2002; **7**: 163-164 [PMID: 11961200 DOI: 10.1634/theoncologist.7-2-163]

35 **Wright M**, Beaty JS, Ternent CA. Molecular Markers for Colorectal Cancer. *Surg Clin North Am* 2017; **97**: 683-701 [PMID: 28501255 DOI: 10.1016/j.suc.2017.01.014]

36 **Grady WM**, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. *Gastroenterology* 2008; **135**: 1079-1099 [PMID: 18773902 DOI: 10.1053/j.gastro.2008.07.076]

37 **Mármol I**, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. *Int J Mol Sci* 2017; **18** [PMID: 28106826 DOI: 10.3390/ijms18010197]

38 **Van Cutsem E**, Nordlinger B, Cervantes A; ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. *Ann Oncol* 2010; **21 Suppl 5**: v93-v97 [PMID: 20555112 DOI: 10.1093/annonc/mdq222]

39 **Van Cutsem E**, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; **25 Suppl 3**: iii1-iii9 [PMID: 25190710 DOI: 10.1093/annonc/mdu260]

40 **Goldstein DA**, Zeichner SB, Bartnik CM, Neustadter E, Flowers CR. Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. *Clin Colorectal Cancer* 2016; **15**: 1-6 [PMID: 26541320 DOI: 10.1016/j.clcc.2015.10.002]

41 **Aparicio J**, Fernandez-Martos C, Vincent JM, Maestu I, Llorca C, Busquier I, Campos JM, Perez-Enguix D, Balcells M. FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. *Clin Colorectal Cancer* 2005; **5**: 263-267 [PMID: 16356303 DOI: 10.3816/ccc.2005.n.037]

42 **Chakrabarti S**, Peterson CY, Sriram D, Mahipal A. Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. *World J Gastrointest Oncol* 2020; **12**: 808-832 [PMID: 32879661 DOI: 10.4251/wjgo.v12.i8.808]

43 **Glimelius B**, Graf W, Hoffman K, Påhlman L, Sjödén PO, Wennberg A. General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. A longitudinal study. *Acta Oncol* 1992; **31**: 645-651 [PMID: 1281650 DOI: 10.3109/02841869209083847]

44 **Ackland SP**, Jones M, Tu D, Simes J, Yuen J, Sargeant AM, Dhillon H, Goldberg RM, Abdi E, Shepherd L, Moore MJ. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. *Br J Cancer* 2005; **93**: 1236-1243 [PMID: 16265352 DOI: 10.1038/sj.bjc.6602841]

45 **Hu Y**, Tao SY, Deng JM, Hou ZK, Liang JQ, Huang QG, Li LH, Li HB, Chen YM, Yi H, Chen XL, Liu H. Prognostic Value of NRAS Gene for Survival of Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. *Asian Pac J Cancer Prev* 2018; **19**: 3001-3008 [PMID: 30484984 DOI: 10.31557/APJCP.2018.19.11.3001]

46 **Peng J**, Lv J, Peng J. KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis. *Int J Colorectal Dis* 2021; **36**: 1781-1790 [PMID: 33760952 DOI: 10.1007/s00384-021-03911-z]

47 **Dai D**, Wang Y, Zhu L, Jin H, Wang X. Prognostic value of KRAS mutation status in colorectal cancer patients: a population-based competing risk analysis. *PeerJ* 2020; **8**: e9149 [PMID: 32547859 DOI: 10.7717/peerj.9149]

48 **Jones RP**, Sutton PA, Evans JP, Clifford R, McAvoy A, Lewis J, Rousseau A, Mountford R, McWhirter D, Malik HZ. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. *Br J Cancer* 2017; **116**: 923-929 [PMID: 28208157 DOI: 10.1038/bjc.2017.37]

49 **Van Cutsem E**, Lenz HJ, Köhne CH, Heinemann V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. *J Clin Oncol* 2015; **33**: 692-700 [PMID: 25605843 DOI: 10.1200/JCO.2014.59.4812]

50 **Peeters M**, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, He P, Yu H, Koukakis R, Terwey JH, Jung AS, Sidhu R, Patterson SD. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. *Clin Cancer Res* 2015; **21**: 5469-5479 [PMID: 26341920 DOI: 10.1158/1078-0432.CCR-15-0526]

51 **Bokemeyer C**, Köhne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH, Tejpar S. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. *Eur J Cancer* 2015; **51**: 1243-1252 [PMID: 25937522 DOI: 10.1016/j.ejca.2015.04.007]

52 **Ikoma T**, Shimokawa M, Kotaka M, Matsumoto T, Nagai H, Boku S, Shibata N, Yasui H, Satake H. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan. *BMC Cancer* 2021; **21**: 518 [PMID: 33962575 DOI: 10.1186/s12885-021-08271-z]

53 **Housman G**, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S. Drug resistance in cancer: an overview. *Cancers (Basel)* 2014; **6**: 1769-1792 [PMID: 25198391 DOI: 10.3390/cancers6031769]

54 **Alfarouk KO**, Stock CM, Taylor S, Walsh M, Muddathir AK, Verduzco D, Bashir AH, Mohammed OY, Elhassan GO, Harguindey S, Reshkin SJ, Ibrahim ME, Rauch C. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. *Cancer Cell Int* 2015; **15**: 71 [PMID: 26180516 DOI: 10.1186/s12935-015-0221-1]

55 **Lu C**, Shervington A. Chemoresistance in gliomas. *Mol Cell Biochem* 2008; **312**: 71-80 [PMID: 18259841 DOI: 10.1007/s11010-008-9722-8]

56 **Brasseur K**, Gévry N, Asselin E. Chemoresistance and targeted therapies in ovarian and endometrial cancers. *Oncotarget* 2017; **8**: 4008-4042 [PMID: 28008141 DOI: 10.18632/oncotarget.14021]

57 **Zhu G**, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. *Mol Cancer* 2021; **20**: 143 [PMID: 34742312 DOI: 10.1186/s12943-021-01441-4]

58 **Yoon HH**, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA; Alliance for Clinical Trials in Oncology. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). *Clin Cancer Res* 2014; **20**: 3033-3043 [PMID: 24687927 DOI: 10.1158/1078-0432.CCR-13-3140]

59 **Yuan S**, Tao F, Zhang X, Zhang Y, Sun X, Wu D. Role of Wnt/β-Catenin Signaling in the Chemoresistance Modulation of Colorectal Cancer. *Biomed Res Int* 2020; **2020**: 9390878 [PMID: 32258160 DOI: 10.1155/2020/9390878]

60 **Bugter JM**, Fenderico N, Maurice MM. Mutations and mechanisms of WNT pathway tumour suppressors in cancer. *Nat Rev Cancer* 2021; **21**: 5-21 [PMID: 33097916 DOI: 10.1038/s41568-020-00307-z]

61 **Gallo G**, Vescio G, De Paola G, Sammarco G. Therapeutic Targets and Tumor Microenvironment in Colorectal Cancer. *J Clin Med* 2021; **10** [PMID: 34070480 DOI: 10.3390/jcm10112295]

62 **Saleh R**, Elkord E. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. *Semin Cancer Biol* 2020; **65**: 13-27 [PMID: 31362073 DOI: 10.1016/j.semcancer.2019.07.017]

63 **Fang H**, Declerck YA. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. *Cancer Res* 2013; **73**: 4965-4977 [PMID: 23913938 DOI: 10.1158/0008-5472.CAN-13-0661]

64 **Gaggianesi M**, Di Franco S, Pantina VD, Porcelli G, D'Accardo C, Verona F, Veschi V, Colarossi L, Faldetta N, Pistone G, Bongiorno MR, Todaro M, Stassi G. Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment. *Front Oncol* 2021; **11**: 702642 [PMID: 34354950 DOI: 10.3389/fonc.2021.702642]

65 **Li X**, Slayton WB. Molecular mechanisms of platelet and stem cell rebound after 5-fluorouracil treatment. *Exp Hematol* 2013; **41**: 635-645.e3 [PMID: 23507524 DOI: 10.1016/j.exphem.2013.03.003]

66 **Fang H**, Ang B, Xu X, Huang X, Wu Y, Sun Y, Wang W, Li N, Cao X, Wan T. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. *Cell Mol Immunol* 2014; **11**: 150-159 [PMID: 24362470 DOI: 10.1038/cmi.2013.59]

67 **Wang D**, Yang L, Yu W, Wu Q, Lian J, Li F, Liu S, Li A, He Z, Liu J, Sun Z, Yuan W, Zhang Y. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance *via* FOXO1/CEBPB/NF-κB signaling. *J Immunother Cancer* 2019; **7**: 215 [PMID: 31395078 DOI: 10.1186/s40425-019-0701-2]

68 **Bagchi S**, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. *Annu Rev Pathol* 2021; **16**: 223-249 [PMID: 33197221 DOI: 10.1146/annurev-pathol-042020-042741]

69 **Robert C**, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med* 2015; **372**: 320-330 [PMID: 25399552 DOI: 10.1056/NEJMoa1412082]

70 **Pires da Silva I**, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, Zimmer L, Trojaniello C, Stout D, Lyle M, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Blank CU, Menzies AM, Long GV. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. *Lancet Oncol* 2021; **22**: 836-847 [PMID: 33989557 DOI: 10.1016/S1470-2045(21)00097-8]

71 **Larkin J**, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med* 2015; **373**: 23-34 [PMID: 26027431 DOI: 10.1056/NEJMoa1504030]

72 **De Sousa Linhares A**, Battin C, Jutz S, Leitner J, Hafner C, Tobias J, Wiedermann U, Kundi M, Zlabinger GJ, Grabmeier-Pfistershammer K, Steinberger P. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. *Sci Rep* 2019; **9**: 11472 [PMID: 31391510 DOI: 10.1038/s41598-019-47910-1]

73 **de Azevedo SJ**, de Melo AC, Roberts L, Caro I, Xue C, Wainstein A. First-line atezolizumab monotherapy in patients with advanced BRAF(V600) wild-type melanoma. *Pigment Cell Melanoma Res* 2021; **34**: 973-977 [PMID: 33476492 DOI: 10.1111/pcmr.12960]

74 **Schmid P**, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. *N Engl J Med* 2018; **379**: 2108-2121 [PMID: 30345906 DOI: 10.1056/NEJMoa1809615]

75 **West H**, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol* 2019; **20**: 924-937 [PMID: 31122901 DOI: 10.1016/S1470-2045(19)30167-6]

76 **O'Donnell JS**, Long GV, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. *Cancer Treat Rev* 2017; **52**: 71-81 [PMID: 27951441 DOI: 10.1016/j.ctrv.2016.11.007]

77 **Chung KY**, Gore I, Fong L, Venook A, Beck SB, Dorazio P, Criscitiello PJ, Healey DI, Huang B, Gomez-Navarro J, Saltz LB. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. *J Clin Oncol* 2010; **28**: 3485-3490 [PMID: 20498386 DOI: 10.1200/JCO.2010.28.3994]

78 **Overman MJ**, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. *Lancet Oncol* 2017; **18**: 1182-1191 [PMID: 28734759 DOI: 10.1016/S1470-2045(17)30422-9]

79 **Kawazoe A**, Itahashi K, Yamamoto N, Kotani D, Kuboki Y, Taniguchi H, Harano K, Naito Y, Suzuki M, Fukutani M, Higuchi T, Ikeno T, Wakabayashi M, Sato A, Koyama S, Nishikawa H, Shitara K. TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704). *Clin Cancer Res* 2021; **27**: 6709-6715 [PMID: 34593531 DOI: 10.1158/1078-0432.CCR-21-1929]

80 **Suzuki S**, Kawakami H, Miike T, Yamamoto S. Complete Remission of Colon Cancer with Ipilimumab Monotherapy. *Intern Med* 2021; **60**: 957-958 [PMID: 33087677 DOI: 10.2169/internalmedicine.6024-20]

81 **Andrews LP**, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. *Immunol Rev* 2017; **276**: 80-96 [PMID: 28258692 DOI: 10.1111/imr.12519]

82 **Haag GM**, Springfeld C, Grün B, Apostolidis L, Zschäbitz S, Dietrich M, Berger AK, Weber TF, Zoernig I, Schaaf M, Waberer L, Müller DW, Al-Batran SE, Halama N, Jaeger D. Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial. *Eur J Cancer* 2022; **167**: 112-122 [PMID: 35427833 DOI: 10.1016/j.ejca.2022.03.017]

83 **Kim JH**, Kim SY, Baek JY, Cha YJ, Ahn JB, Kim HS, Lee KW, Kim JW, Kim TY, Chang WJ, Park JO, Kim J, Kim JE, Hong YS, Kim YH, Kim TW. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer. *Cancer Res Treat* 2020; **52**: 1135-1144 [PMID: 32340084 DOI: 10.4143/crt.2020.218]

84 **Oh CR**, Kim JE, Hong YS, Kim SY, Ahn JB, Baek JY, Lee MA, Kang MJ, Cho SH, Beom SH, Kim TW. Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer. *Int J Cancer* 2022; **150**: 2038-2045 [PMID: 35179785 DOI: 10.1002/ijc.33966]

85 **Kanikarla Marie P**, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. *Clin Cancer Res* 2021; **27**: 3039-3049 [PMID: 33811152 DOI: 10.1158/1078-0432.CCR-21-0163]

86 **Lenz HJ**, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledeine JM, Overman MJ, Lonardi S. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. *J Clin Oncol* 2022; **40**: 161-170 [PMID: 34637336 DOI: 10.1200/JCO.21.01015]

87 **Morse MA**, Overman MJ, Hartman L, Khoukaz T, Brutcher E, Lenz HJ, Atasoy A, Shangguan T, Zhao H, El-Rayes B. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. *Oncologist* 2019; **24**: 1453-1461 [PMID: 31147488 DOI: 10.1634/theoncologist.2019-0129]

88 **Kasi PM**, Budde G, Krainock M, Aushev VN, Koyen Malashevich A, Malhotra M, Olshan P, Billings PR, Aleshin A. Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer. *J Immunother Cancer* 2022; **10** [PMID: 35101943 DOI: 10.1136/jitc-2021-003312]

89 **Johnson B**, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). *J Immunother Cancer* 2022; **10** [PMID: 36007963 DOI: 10.1136/jitc-2022-005332]

90 **Cohen R**, Bennouna J, Meurisse A, Tournigand C, De La Fouchardière C, Tougeron D, Borg C, Mazard T, Chibaudel B, Garcia-Larnicol ML, Svrcek M, Vernerey D, Menu Y, André T. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. *J Immunother Cancer* 2020; **8** [PMID: 33148693 DOI: 10.1136/jitc-2020-001499]

91 **Eng C**, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators. Atezolizumab with or without cobimetinib *vs* regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncol* 2019; **20**: 849-861 [PMID: 31003911 DOI: 10.1016/S1470-2045(19)30027-0]

92 **Hellmann MD**, Kim TW, Lee CB, Goh BC, Miller WH Jr, Oh DY, Jamal R, Chee CE, Chow LQM, Gainor JF, Desai J, Solomon BJ, Das Thakur M, Pitcher B, Foster P, Hernandez G, Wongchenko MJ, Cha E, Bang YJ, Siu LL, Bendell J. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. *Ann Oncol* 2019; **30**: 1134-1142 [PMID: 30918950 DOI: 10.1093/annonc/mdz113]

93 **Fumet JD**, Isambert N, Hervieu A, Zanetta S, Guion JF, Hennequin A, Rederstorff E, Bertaut A, Ghiringhelli F. Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer. *ESMO Open* 2018; **3**: e000375 [PMID: 29942666 DOI: 10.1136/esmoopen-2018-000375]

94 **Antoniotti C**, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino F, Moretto R, Ambrosini M, Tamburini E, Tortora G, Passardi A, Bergamo F, Kassambara A, Sbarrato T, Morano F, Ritorto G, Borelli B, Boccaccino A, Conca V, Giordano M, Ugolini C, Fieschi J, Papadopulos A, Massoué C, Aprile G, Antonuzzo L, Gelsomino F, Martinelli E, Pella N, Masi G, Fontanini G, Boni L, Galon J, Cremolini C; GONO Foundation Investigators. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. *Lancet Oncol* 2022; **23**: 876-887 [PMID: 35636444 DOI: 10.1016/S1470-2045(22)00274-1]

95 **Tabernero J**, Grothey A, Arnold D, de Gramont A, Ducreux M, O'Dwyer P, Tahiri A, Gilberg F, Irahara N, Schmoll HJ, Van Cutsem E. MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF(wt) metastatic colorectal cancer. *ESMO Open* 2022; **7**: 100559 [PMID: 36029653 DOI: 10.1016/j.esmoop.2022.100559]

96 **Martinelli E**, Martini G, Famiglietti V, Troiani T, Napolitano S, Pietrantonio F, Ciardiello D, Terminiello M, Borrelli C, Vitiello PP, De Braud F, Morano F, Avallone A, Normanno N, Nappi A, Maiello E, Latiano T, Falcone A, Cremolini C, Rossini D, Santabarbara G, Pinto C, Santini D, Cardone C, Zanaletti N, Di Liello A, Renato D, Esposito L, Marrone F, Ciardiello F. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. *JAMA Oncol* 2021; **7**: 1529-1535 [PMID: 34382998 DOI: 10.1001/jamaoncol.2021.2915]

97 **Stein A**, Simnica D, Schultheiß C, Scholz R, Tintelnot J, Gökkurt E, von Wenserski L, Willscher E, Paschold L, Sauer M, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, Ettrich TJ, Dörfel S, Al-Batran SE, Karthaus M, Pelzer U, Waberer L, Hinke A, Bauer M, Massa C, Seliger B, Wickenhauser C, Bokemeyer C, Hegewisch-Becker S, Binder M. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. *J Immunother Cancer* 2021; **9** [PMID: 34315821 DOI: 10.1136/jitc-2021-002844]

98 **Ciardiello D**, Famiglietti V, Napolitano S, Esposito L, Pietrantonio F, Avallone A, Maiello E, Cremolini C, Troiani T, Martinelli E, Ciardiello F, Martini G. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. *Clin Colorectal Cancer* 2022; **21**: 141-148 [PMID: 35101346 DOI: 10.1016/j.clcc.2022.01.005]

99 **Cousin S**, Cantarel C, Guegan JP, Gomez-Roca C, Metges JP, Adenis A, Pernot S, Bellera C, Kind M, Auzanneau C, Le Loarer F, Soubeyran I, Bessede A, Italiano A. Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial. *Clin Cancer Res* 2021; **27**: 2139-2147 [PMID: 33495314 DOI: 10.1158/1078-0432.CCR-20-3416]

100 **Segal NH**, Cercek A, Ku G, Wu AJ, Rimner A, Khalil DN, Reidy-Lagunes D, Cuaron J, Yang TJ, Weiser MR, Romesser PB, Stadler ZK, Varghese AM, Ganesh K, Yaeger R, Connell LC, Faleck D, Abou-Alfa GK, Mcauliffe KC, Vaiskauskas P, Solter ML, Ogle M, Adamow MJ, Holland A, Vedantam P, Wong P, Merghoub T, Vakiani E, Hollmann TJ, Juluru K, Chou JF, Capanu M, Erinjeri J, Solomon S, Yamada Y, Kemeny N, Crane CH, Saltz LB. Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. *Clin Cancer Res* 2021; **27**: 2200-2208 [PMID: 33504552 DOI: 10.1158/1078-0432.CCR-20-2474]

101 **Redman JM**, Tsai YT, Weinberg BA, Donahue RN, Gandhy S, Gatti-Mays ME, Abdul Sater H, Bilusic M, Cordes LM, Steinberg SM, Marte JL, Jochems C, Kim SS, Marshall JL, McMahon S, Redmond E, Schlom J, Gulley JL, Strauss J. A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. *Oncologist* 2022; **27**: 198-209 [PMID: 35274710 DOI: 10.1093/oncolo/oyab046]

102 **Chen EX**, Jonker DJ, Loree JM, Kennecke HF, Berry SR, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M, Colwell B, Samimi S, Samson B, Abbas T, Aucoin N, Aubin F, Koski SL, Wei AC, Magoski NM, Tu D, O'Callaghan CJ. Effect of Combined Immune Checkpoint Inhibition *vs* Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study. *JAMA Oncol* 2020; **6**: 831-838 [PMID: 32379280 DOI: 10.1001/jamaoncol.2020.0910]

103 **Randrian V**, Pernot S, Le Malicot K, Catena V, Baumgaertner I, Tacher V, Forestier J, Hautefeuille V, Tabouret-Viaud C, Gagnaire A, Mitry E, Guiu B, Aparicio T, Smith D, Dhomps A, Tasu JP, Perdrisot R, Edeline J, Capron C, Cheze-Le Rest C, Emile JF, Laurent-Puig P, Bejan-Angoulvant T, Sokol H, Lepage C, Taieb J, Tougeron D. FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer. *Dig Liver Dis* 2022; **54**: 857-863 [PMID: 35610167 DOI: 10.1016/j.dld.2022.04.024]

104 **Lau D**, Kalaitzaki E, Church DN, Pandha H, Tomlinson I, Annels N, Gerlinger M, Sclafani F, Smith G, Begum R, Crux R, Gillbanks A, Wordsworth S, Chau I, Starling N, Cunningham D, Dhillon T. Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. *ESMO Open* 2020; **5** [PMID: 32079623 DOI: 10.1136/esmoopen-2019-000638]

105 **Ryman JT**, Meibohm B. Pharmacokinetics of Monoclonal Antibodies. *CPT Pharmacometrics Syst Pharmacol* 2017; **6**: 576-588 [PMID: 28653357 DOI: 10.1002/psp4.12224]

106 **Wang J**, Giragossian C, Hansel S. Analyze impact of tumor-associated kinetics on antibody delivery in solid tumors with a physiologically based pharmacokinetics/pharmacodynamics model. *Eur J Pharm Biopharm* 2021; **168**: 110-121 [PMID: 34478854 DOI: 10.1016/j.ejpb.2021.08.019]

107 **Gawel DR**, Serra-Musach J, Lilja S, Aagesen J, Arenas A, Asking B, Bengnér M, Björkander J, Biggs S, Ernerudh J, Hjortswang H, Karlsson JE, Köpsen M, Lee EJ, Lentini A, Li X, Magnusson M, Martínez-Enguita D, Matussek A, Nestor CE, Schäfer S, Seifert O, Sonmez C, Stjernman H, Tjärnberg A, Wu S, Åkesson K, Shalek AK, Stenmarker M, Zhang H, Gustafsson M, Benson M. A validated single-cell-based strategy to identify diagnostic and therapeutic targets in complex diseases. *Genome Med* 2019; **11**: 47 [PMID: 31358043 DOI: 10.1186/s13073-019-0657-3]

108 **Hu P**, Zhang W, Xin H, Deng G. Single Cell Isolation and Analysis. *Front Cell Dev Biol* 2016; **4**: 116 [PMID: 27826548 DOI: 10.3389/fcell.2016.00116]

109 **Gibney GT**, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. *Lancet Oncol* 2016; **17**: e542-e551 [PMID: 27924752 DOI: 10.1016/S1470-2045(16)30406-5]

110 **Dancsok AR**, Gao D, Lee AF, Steigen SE, Blay JY, Thomas DM, Maki RG, Nielsen TO, Demicco EG. Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. *Oncoimmunology* 2020; **9**: 1747340 [PMID: 32313727 DOI: 10.1080/2162402X.2020.1747340]

111 **Solinas C**, De Silva P, Bron D, Willard-Gallo K, Sangiolo D. Significance of TIM3 expression in cancer: From biology to the clinic. *Semin Oncol* 2019; **46**: 372-379 [PMID: 31733828 DOI: 10.1053/j.seminoncol.2019.08.005]

112 **Olguín JE**, Medina-Andrade I, Molina E, Vázquez A, Pacheco-Fernández T, Saavedra R, Pérez-Plasencia C, Chirino YI, Vaca-Paniagua F, Arias-Romero LE, Gutierrez-Cirlos EB, León-Cabrera SA, Rodriguez-Sosa M, Terrazas LI. Early and Partial Reduction in CD4(+)Foxp3(+) Regulatory T Cells during Colitis-Associated Colon Cancer Induces CD4(+) and CD8(+) T Cell Activation Inhibiting Tumorigenesis. *J Cancer* 2018; **9**: 239-249 [PMID: 29344269 DOI: 10.7150/jca.21336]

113 **Sakuishi K**, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, Anderson AC. TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. *Oncoimmunology* 2013; **2**: e23849 [PMID: 23734331 DOI: 10.4161/onci.23849]

114 **Curigliano G**, Gelderblom H, Mach N, Doi T, Tai D, Forde PM, Sarantopoulos J, Bedard PL, Lin CC, Hodi FS, Wilgenhof S, Santoro A, Sabatos-Peyton CA, Longmire TA, Xyrafas A, Sun H, Gutzwiller S, Manenti L, Naing A. Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. *Clin Cancer Res* 2021; **27**: 3620-3629 [PMID: 33883177 DOI: 10.1158/1078-0432.CCR-20-4746]

115 **Tian J**, Zhang B, Rui K, Wang S. The Role of GITR/GITRL Interaction in Autoimmune Diseases. *Front Immunol* 2020; **11**: 588682 [PMID: 33163004 DOI: 10.3389/fimmu.2020.588682]

116 **Geva R**, Voskoboynik M, Dobrenkov K, Mayawala K, Gwo J, Wnek R, Chartash E, Long GV. First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. *Cancer* 2020; **126**: 4926-4935 [PMID: 32809217 DOI: 10.1002/cncr.33133]

117 **Huard B**, Tournier M, Hercend T, Triebel F, Faure F. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. *Eur J Immunol* 1994; **24**: 3216-3221 [PMID: 7805750 DOI: 10.1002/eji.1830241246]

118 **de Klerk LK**, Patel AK, Derks S, Pectasides E, Augustin J, Uduman M, Raman N, Akarca FG, McCleary NJ, Cleary JM, Rubinson DA, Clark JW, Fitzpatrick B, Brais LK, Cavanaugh ME, Rode AJ, Jean MG, Lizotte PH, Nazzaro MJ, Severgnini M, Zheng H, Fuchs CS, Enzinger PC, Bass AJ. Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. *J Immunother Cancer* 2021; **9** [PMID: 34593617 DOI: 10.1136/jitc-2021-002472]

119 **Kim M**, Min YK, Jang J, Park H, Lee S, Lee CH. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer. *J Immunother Cancer* 2021; **9** [PMID: 34253638 DOI: 10.1136/jitc-2021-002503]

120 **Turiello R**, Pinto A, Morello S. CD73: A Promising Biomarker in Cancer Patients. *Front Pharmacol* 2020; **11**: 609931 [PMID: 33364969 DOI: 10.3389/fphar.2020.609931]

121 **Thibaudin M**, Limagne E, Hampe L, Ballot E, Truntzer C, Ghiringhelli F. Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer. *Cancer Immunol Immunother* 2022; **71**: 2549-2563 [PMID: 35292828 DOI: 10.1007/s00262-022-03182-9]

122 **Chauvin JM**, Zarour HM. TIGIT in cancer immunotherapy. *J Immunother Cancer* 2020; **8** [PMID: 32900861 DOI: 10.1136/jitc-2020-000957]

123 **Español-Rego M**, Fernández-Martos C, Elez E, Foguet C, Pedrosa L, Rodríguez N, Ruiz-Casado A, Pineda E, Cid J, Cabezón R, Oliveres H, Lozano M, Ginés A, García-Criado A, Ayuso JR, Pagés M, Cuatrecasas M, Torres F, Thomson T, Cascante M, Benítez-Ribas D, Maurel J. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study. *Cancer Immunol Immunother* 2022 [PMID: 36083313 DOI: 10.1007/s00262-022-03283-5]

124 **Zhang Z**, Lu M, Qin Y, Gao W, Tao L, Su W, Zhong J. Neoantigen: A New Breakthrough in Tumor Immunotherapy. *Front Immunol* 2021; **12**: 672356 [PMID: 33936118 DOI: 10.3389/fimmu.2021.672356]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** September 24, 2022

**First decision:** October 20, 2022

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** Mexico

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Tantau AI, Romania; Wismayer R, Uganda **S-Editor:** Gao CC **L-Editor:** Filipodia **P-Editor:**


**Figure Legends**



**Figure 1 5-Fluorouracil mechanism of action.** The 5-fluorouracil structure is analogous to that of the nucleotide uracil; its ability to disrupt standard RNA processing and function is mediated by three primary metabolites: fluorodeoxyuridine monophosphate, fluorodeoxyuridine diphosphate, and fluorouridine triphosphate. 1: 5-fluorouracil inhibits thymidylate synthase activity by fluorodeoxyuridine monophosphate metabolite binding, blocking the typical substrate deoxyuridine monophosphate that inhibits deoxythymidine monophosphate synthesis leading to deoxythymidine triphosphate imbalance. The consequent result is DNA damage due to a deficiency in its synthesis and its repair; 2: DNA replication and repair are regulated by deoxyuridine monophosphate transition to deoxythymidine monophosphate. This step is coordinated by thymidylate synthase; FUMP: Fluorodeoxyuridine monophosphate; FUDP: Fluorodeoxyuridine diphosphate; FUTP: Fluorouridine triphosphate; dUMP: Deoxyuridine monophosphate; dTMP: Deoxythymidine monophosphate; FUDR: Fluorodeoxyuridine; FdUMP: Fluorodeoxyuridine monophosphate; dTTP: Deoxythymidine triphosphate; FdUDP: Fluorodeoxyuridine diphosphate; FdUTP: Fluorodeoxyuridine triphosphate; 5-FU: 5-Fluorouracil; TS: Thymidylate synthase.



**Figure 2 Mechanism of action using either anti-programmed cell death ligand 1 or anti-nonclassical immune checkpoint inhibitor antibodies to increase the effector immune response in colorectal cancer.** A: The programmed cell death ligand 1 molecule expressed on both tumor and myeloid suppressor cells interacts with programmed cell death 1 molecules expressed on exhausted CD8+ and CD4+ T cells, inducing a state of anergy. Additionally, other nonclassical immune checkpoint inhibitor molecules can induce anergy in T cells; B: Anti-programmed cell death ligand 1 antibodies block the interaction of the programmed cell death 1/programmed cell death ligand 1 axis, favoring the return from the state of anergy to exert the effector function of CD4+ and CD8+ T cells, favoring the reduction of the tumor burden. Most likely, nonclassical immune checkpoint inhibitor antibodies may have a similar effect; C: Once CD4+ T cells are activated, they produce cytokines for the efficient activation of CD8+ T cells, which in turn produce granzyme and perforin, inducing apoptosis in tumor cells. The addition of chemotherapeutic drugs increases the induction of neoantigens, favoring immune response activation. PDL1: Programmed cell death ligand 1; PD1: Programmed cell death 1; ICI: Immune checkpoint inhibitor.



**Figure 3 The tumor microenvironment favors or does not allow the access of both classical and nonclassical immune checkpoint inhibitors to their targets in immune cells.** A: The classical immune checkpoint inhibitor (ICI) antibody cannot access its target because immune cells are surrounded by tumor cells, although immune cells may express classical ICIs; B: On the other hand, classical ICIs probably have access to immune cells but may not express the targeting molecules; C: Chemotherapy can induce the death of tumoral cells, favoring the formation of neoantigens that may reactivate immune cells. Additional classical ICI antibodies target individual molecules such as cytotoxic T-lymphocyte-associated protein 4, programmed cell death 1, and programmed cell death ligand 1; D: Finally, immune cells expressing nonclassical ICIs could have effector profiles such as helper T type 1 cells, cytotoxic T cells, M1, or N1 when nonclassical antibodies target them. Additionally, tumor epithelial cells may likely express both classical and nonclassical ICIs. ICI: Immune checkpoint inhibitor.

**Table 1 Types of immune checkpoint inhibitor antibodies used as monotherapy, combined immune checkpoint inhibitor, and immune checkpoint inhibitor + chemotherapy in colorectal cancer**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Antibody name** | **Isotype** | **Target molecule** | **Effectiveness1 as monotherapy** | **Effectiveness as combined ICI** | **Effectiveness as ICI + chemotherapy** | **Ref.** |
| Ipilimumab | IgG1 | CTLA4 | Yes | Well tolerated in combination with nivolumab | No | Suzuki *et al*[80], 2021; Lenz *et al*[86], 2022; Cohen *et al*[90], 2020 |
| Tremelimumab | IgG2 | CTLA4 | No | Yes, durvalumab improved OS and increased lymphoid response | Combined with durvalumab + fluoropyrimidines, oxaliplatin, irinotecan, showed increased OS | Chung *et al*[77], 2010; Kanikarla Marie *et al*[85], 2021; Chen *et al*[102], 2020 |
| Nivolumab | IgG4 | PD1 | Well tolerated | Well tolerated in combination with low ipilimumab dose, with increased OS | Yes | Overman *et al*[78], 2017; Kawazoe *et al*[79], 2021; Lenz *et al*[86], 2022; Morse *et al*[87], 2019 |
| Pembrolizumab | IgG4 | PD1 | Well tolerated, increased OS | No | There is no evidence | Haag *et al*[82], 2022 |
| Atezolizumab | IgG1 | PDL1 | There is no evidence | There is no evidence | Safe when combined with cobimetinib, having no effect on OS. Combined with FOLFOX and bevacizumab showed increased progression-free survival, but adverse events were shown | Eng *et al*[91], 2019; Antoniotti *et al*[94], 2022 |
| Avelumab | IgG1 | PDL1 | Increased OS but adverse events were shown | There is no evidence | Combined with cetuximab showed increased T cell killing | Haag *et al*[82], 2022; Stein *et al*[97], 2021 |
| Durvalumab | IgG1 | PDL1 | Increased progression-free survival, but adverse events were shown | There is no evidence | Safe when combined with MEKi, having no effect on OS | Oh *et al*[84], 2022 |

1Effectiveness was considered as increased survival, well tolerated treatment in patients, or simply a lack of side effects associated with the treatment. IgG: Immunoglobulin G; OS: Overall survival; PDL1: Programmed cell death ligand 1; PD1: Programmed cell death 1; CTLA4: Cytotoxic T-lymphocyte-associated protein 4; ICI: Immune checkpoint inhibitor; FOLFOX: 5-FU therapy with leucovorin and oxaliplatin; MEKi: Inhibitor of MAPK/ERK kinase.